Efficacy and safety of dalbavancin as suppressive therapy in chronic implant-associated infections
Long-acting lipoglycopeptides represent an innovative suppressive antimicrobial therapy (SAT) for Gram-positive chronic infections. We aimed to describe the off-label use of dalbavancin SAT.
